.Pharmacolibrary.Drugs.ATC.J.J05AR12 .Pharmacolibrary.Drugs.ATC.J.J05AR12| name: | LamivudineAndTenofovirDisoproxil |
| ATC code: | J05AR12 | route: | oral |
| n-compartments | 1 |
Lamivudine and tenofovir disoproxil are antiretroviral medications used in combination for the treatment of HIV-1 infection in adults and adolescents, and also for chronic hepatitis B infection (tenofovir). Both drugs are approved and recommended as first-line therapy by major guidelines.
Population pharmacokinetic parameters from published studies of HIV-infected adults, both sexes, receiving oral fixed-dose combination tablets of lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg once daily.
Bednasz, CJ, et al., & Morse, GD (2019). Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202. Antimicrobial agents and chemotherapy 63(4) –. DOI:10.1128/AAC.01638-18 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30642925
De Sousa Mendes, M, et al., & Benaboud, S (2015). Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. British journal of clinical pharmacology 80(5) 1031–1041. DOI:10.1111/bcp.12685 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26011128